TransMedics (Nasdaq:TMDX) received FDA investigational device exemption (IDE) for its next-generation OCS ENHANCE Heart trial.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn't get the organ to a recipient in time.

The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...

The emerging advantages of positron-emission tomography (PET) myocardial perfusion imaging (MPI) for coronary artery disease (CAD) diagnosis and assessment of cardiovascular event risk has prompted ...

Using the Organ Care System (OCS) Heart platform to perfuse, optimize, and assess donor hearts has excellent outcomes, including 87% of extended criteria donor (ECD) hearts being successfully ...

In the majority of cases, graft failure after heart transplantation is attributable to abnormalities like severe coronary artery disease. As donors with extended criteria like advanced age and ...

TransMedics Group Inc (NASDAQ:TMDX) stock jumped 6.7% after the company announced that the U.S. Food and Drug Administration (FDA) granted conditional approval for its Investigational Device Exemption ...

Perfusion describes when fluids such as blood and lymph pass through tissue. A perfusionist is a professional who operates machinery when this process requires assistance, such as during heart surgery ...